Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Riga, Latvia Clinical Trials

A listing of Riga, Latvia clinical trials actively recruiting patients volunteers.

RESULTS

Found (10) clinical trials

Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

This is a multicenter, open-label study comprised of pretreatment, treatment (core study), and extension phases that is designed to evaluate the PK of an oral suspension of perampanel (target dose of 12 milligrams per day [mg /day] for non-enzyme-inducing antiepileptic drug [non-EIAED] or 16 mg/day for EIAED) when given as ...

Phase

0.0 miles

Learn More »

FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty

This study is to compare the study drug BAY1213790 to existing therapies, ie Enoxaparin or Apixaban for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA). The study is open-label, but observer-blind for the different doses of BAY1213790 administered. This means that it is known ...

Phase

0.0 miles

Learn More »

A Study to Investigate Efficacy Safety Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis

The purpose of this study is to investigate efficacy, safety and tolerability of ASP6294 in female participants with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC). This study will also investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of ASP6294 in female participants with BPS/IC.

Phase

0.0 miles

Learn More »

A Study of an Investigational Drug Cemdisiran (ALN-CC5) in Patients With Atypical Hemolytic Uremic Syndrome

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Cemdisiran in patients with aHUS.

Phase

0.0 miles

Learn More »

ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

To assess the safety of intravitreal Zimura (complement factor C5 inhibitor) administered in combination with Lucentis 0.5 mg in treatment nave subjects with neovascular age related macular degeneration (NVAMD)

Phase

0.46 miles

Learn More »

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

The primary objective of the study is to evaluate the time to resolution of influenza symptoms in adults with acute uncomplicated seasonal influenza A following administration of VX-787, with and without concomitant oseltamivir.

Phase

0.64 miles

Learn More »

Study of VIS410 in Subjects With Uncomplicated Influenza A

Subjects will be admitted to an infusion unit for drug administration and observation following infusion. The study is designed to compare an infusion of a single high or low IV dose of VIS410 against placebo. Subjects will be followed for 100 (±7 days).

Phase

0.64 miles

Learn More »

Endovascular NeuromoDulation Treatment fOr Heart Failure Patients (ENDO-HF)

The purpose of the ENDO-HF study is to determine the safety & performance of the Harmony System for the treatment of heart failure

Phase

1.89 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

This study has 2 parts, dose escalation and dose-response evaluation, and will be conducted in participants undergoing primary unilateral elective Total Knee Replacement (TKR) surgery. Participants will participate in either Part 1 or Part 2 of study only. The study will be conducted in 3 phases: an up to 30-day ...

Phase

1.94 miles

Learn More »

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum doublet induction chemotherapy.

Phase

5.33 miles

Learn More »